Keros Therapeutics Inc · Q1 2024 earnings

Briefing

Keros Therapeutics experienced increased research and development efforts and investments to support clinical and corporate goals.

Keros Therapeutics reported a net loss of $43.1 million for the first quarter of 2024, compared to a net loss of $35.8 million for the same period in 2023. The increase in net loss was primarily due to increased research and development expenses and general and administrative expenses. Cash and cash equivalents totaled $442.4 million as of March 31, 2024.

• Keros is focused on clinical execution and made strong progress across the pipeline.
• An update on the planned Phase 3 clinical trial of KER-050 in patients with myelodysplastic syndromes is expected in mid-2024.
• Keros will present a poster abstract from its KER-012 program at the American Thoracic Society (“ATS”) 2024 International Conference.
• Cash and cash equivalents are expected to fund operating expenses and capital expenditure requirements into 2027.

Headline financials

Revenue & EPS history

Keros expects that the cash and cash equivalents it had on hand at March 31, 2024 will enable Keros to fund its operating expenses and capital expenditure requirements into 2027.